title: Vandetanib: a guide to its use in advanced medullary thyroid cancer.
abstract: Vandetanib (Caprelsa™) provides an acceptable treatment option in patients with advanced medullary thyroid cancer for whom, historically, there have been no effective therapies. Vandetanib, an orally active, multitargeted tyrosine kinase inhibitor, improves progression-free survival and tumor response in patients with unresectable, locally advanced or metastatic medullary thyroid cancer. It has an acceptable tolerability profile in this patient population, although it does have the potential to prolong the corrected QT interval.
authors.affiliation: Adis, Auckland, New Zealand. demail@springer.com
authors.forename: Gillian M
authors.initials: GM
authors.lastname: Keating
authors.forename: Katherine A
authors.initials: KA
authors.lastname: Lyseng-Williamson
authors.forename: James E
authors.initials: JE
authors.lastname: Frampton
mesh_terms: D018278:Carcinoma, Neuroendocrine; D018572:Disease-Free Survival; D006801:Humans; D009361:Neoplasm Invasiveness; D009362:Neoplasm Metastasis; D010880:Piperidines / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011799:Quinazolines / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D013964:Thyroid Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology
chemical_list: D010880:Piperidines; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D011505:Protein-Tyrosine Kinases; C452423:vandetanib